Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of -altered non-small cell lung cancer.
Dennis Ruder,Vassiliki Papadimitrakopoulou,Kazuhiko Shien,Carmen Behrens,Neda Kalhor,Huiqin Chen,Li Shen,J. Jack Lee,Waun Ki Hong,Ximing Tang,Luc Girard,John D. Minna,Lixia Diao,Jing Wang,Barbara Mino,Pamela Villalobos,Jaime Rodriguez-Canales,Nana E. Hanson,James Sun,Vincent A. Miller,Joel Greenbowe,Garrett M. Frampton,Roy S. Herbst,Veera Baladandayuthapani,Ignacio I. Wistuba,Julie G Izzo
DOI: https://doi.org/10.18632/oncotarget.26129
2018-01-01
Oncotarget
Abstract:// Dennis Ruder 1, 2 , Vassiliki Papadimitrakopoulou 4 , Kazuhiko Shien 2 , Carmen Behrens 4 , Neda Kalhor 5 , Huiqin Chen 6 , Li Shen 3 , J. Jack Lee 6 , Waun Ki Hong 4 , Ximing Tang 2 , Luc Girard 7 , John D. Minna 7 , Lixia Diao 3 , Jing Wang 3 , Barbara Mino 2 , Pamela Villalobos 2 , Jaime Rodriguez-Canales 2 , Nana E. Hanson 2 , James Sun 9 , Vincent Miller 9 , Joel Greenbowe 9 , Garrett Frampton 9 , Roy S. Herbst 8 , Veera Baladandayuthapani 6 , Ignacio I. Wistuba 2 and Julie G. Izzo 2 1 Graduate Program in Human and Molecular Genetics and Cancer Biology, MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, Texas, USA 2 Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA 3 Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA 4 Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA 5 Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA 6 Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA 7 Hamon Center for Therapeutic Oncology Research, The University of Texas Southwestern Medical Center, Dallas, Texas, USA 8 Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut, USA 9 Foundation Medicine, Inc., Cambridge, Massachusetts, USA Correspondence to: Julie G. Izzo, email: jizzo@mdanderson.org Ignacio I. Wistuba, email: iiwistuba@mdanderson.org Keywords: RICTOR gene abnormalities; KRAS mutation; MAPK pathway; mTORC2; non-small cell lung cancer Received: April 13, 2018 Accepted: September 09, 2018 Published: September 21, 2018 ABSTRACT Despite a therapeutic paradigm shift into targeted-driven medicinal approaches, resistance to therapy remains a hallmark of lung cancer, driven by biological and molecular diversity. Using genomic and expression data from advanced non-small cell lung cancer (NSCLC) patients enrolled in the BATTLE-2 clinical trial, we identified RICTOR alterations in a subset of lung adenocarcinomas and found RICTOR expression to carry worse overall survival. RICTOR-altered cohort was significantly enriched in KRAS/MAPK axis mutations, suggesting a co-oncogenic driver role in these molecular settings. Using NSCLC cell lines, we showed that, distinctly in KRAS mutant backgrounds, RICTOR blockade impairs malignant properties and generates a compensatory enhanced activation of the MAPK pathway, exposing a unique therapeutic vulnerability. In vitro and in vivo concomitant pharmacologic inhibition of mTORC1/2 and MEK1/2 resulted in synergistic responses of anti-tumor effects. Our study provides evidence of a distinctive therapeutic opportunity in a subset of NSCLC carrying concomitant RICTOR/KRAS alterations.